Literature DB >> 26828755

Polymorphisms in NRGN are associated with schizophrenia, major depressive disorder and bipolar disorder in the Han Chinese population.

Zujia Wen1, Jianhua Chen2, Raja Amjad Waheed Khan1, Meng Wang1, Zhijian Song1, Zhiqiang Li1, Jiawei Shen1, Wenjin Li1, Yongyong Shi3.   

Abstract

BACKGROUND: The NRGN gene locates on 11q24 and encodes a postsynaptic protein kinase substrate that binds calmodulin in the absence of calcium. In a previous genome-wide association study of schizophrenia in the Caucasian population, rs12807809 of NRGN was found to be significantly associated with schizophrenia, moreover, it was further found to be associated with bipolar disorder.
METHODS: We recruited 1248 schizophrenia cases, 1344 bipolar disorder cases, 1056 major depressive disorder cases, and 1248 healthy controls from Han Chinese population. Rs12807809 and another two tag SNPs of NRGN were genotyped and analyzed in three diseases respectively. A meta-analysis of rs12807809 was also conducted to verify its association with schizophrenia in Han Chinese population.
RESULTS: Rs7113041 was associated with bipolar disorder (odds ratio, 95% confidence interval (OR, 95% CI)=1.194, 1.032-1.383; Pgenotype=0.0126), and rs12278912 was associated with major depressive disorder (OR, 95% CI=0.789, 0.673-0.924; Pallele=0.0102, Pgenotype=0.0399) after Bonferroni correction. The "GA" haplotype of rs7113041-rs12278912 was significantly associated with schizophrenia, major depressive disorder and bipolar disorder (corresponding P values were 2.85E-04, 3.00E-03, and 5.40E-04 after Bonferroni correction). LIMITATIONS: Despite the association between NRGN and psychoses we have found, we failed to validate the positive variant rs12807809, which was reported in the Caucasian genome-wide association study both in our single site association test and the meta-analysis. Functional studies are needed to illuminate the role of NRGN in the pathogenesis of these mental disorders.
CONCLUSIONS: Our findings prove that NRGN is a shared susceptibility gene of schizophrenia, major depression and bipolar disorder in Han Chinese, and this might provide a new target for the diagnosis and treatment of these mental disorders.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26828755     DOI: 10.1016/j.jad.2016.01.034

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  6 in total

Review 1.  Perspective on Etiology and Treatment of Bipolar Disorders in China: Clinical Implications and Future Directions.

Authors:  Zuowei Wang; Chen Jun; Keming Gao; Haichen Yang; Yiru Fang
Journal:  Neurosci Bull       Date:  2019-05-16       Impact factor: 5.203

2.  Electroconvulsive therapy does not alter the synaptic protein neurogranin in the cerebrospinal fluid of patients with major depression.

Authors:  Laura Kranaster; Kaj Blennow; Henrik Zetterberg; Alexander Sartorius
Journal:  J Neural Transm (Vienna)       Date:  2017-10-23       Impact factor: 3.575

3.  Neurogranin-like immunoreactivity in the zebrafish brain during development.

Authors:  Anabel Alba-González; Julián Yáñez; Ramón Anadón; Mónica Folgueira
Journal:  Brain Struct Funct       Date:  2022-08-26       Impact factor: 3.748

Review 4.  A Systematic Review of Candidate Genes for Major Depression.

Authors:  Audrone Norkeviciene; Romena Gocentiene; Agne Sestokaite; Rasa Sabaliauskaite; Daiva Dabkeviciene; Sonata Jarmalaite; Giedre Bulotiene
Journal:  Medicina (Kaunas)       Date:  2022-02-14       Impact factor: 2.430

5.  Association between NRGN gene polymorphism and resting-state hippocampal functional connectivity in schizophrenia.

Authors:  Yifan Zhang; Xiaohong Gong; Zhiyang Yin; Lingling Cui; Jian Yang; Pengshuo Wang; Yifang Zhou; Xiaowei Jiang; Shengnan Wei; Fei Wang; Yanqing Tang
Journal:  BMC Psychiatry       Date:  2019-04-05       Impact factor: 3.630

6.  The association between rs12807809 polymorphism in neurogranin gene and risk of schizophrenia: A meta-analysis.

Authors:  Lu Jin; Zhiguo An; Bin Xu; Daibin Mu; Songnian Fu; Hongxing Hu; Yongyong Shi; Xiao Luo; Qizhong Yi
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.